Xenon Pharmaceuticals (NASDAQ: XENE) revenue
Xenon Pharmaceuticals reported revenue of $7.5m for fiscal 2025; in fiscal 2024 it was $0.0m. Since fiscal 2016 its revenue has grown by 316.0%, an average growth of 17.2% a year.
Xenon Pharmaceuticals's best year of the last 9 was fiscal 2020. The biggest drop was in fiscal 2017, −82.8%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $7.5m | — | −$373.1m | −4,974.3% |
| 2024 | $0.0m | — | −$279.3m | — |
| 2023 | $0.0m | −100.0% | −$214.1m | — |
| 2022 | $9.4m | −48.8% | −$129.1m | −1,368.9% |
| 2021 | $18.4m | −42.7% | −$79.0m | −428.4% |
| 2020 | $32.2m | +371.0% | −$31.3m | −97.3% |
| 2019 | $6.8m | — | −$42.8m | −627.0% |
| 2017 | $0.3m | −82.8% | −$32.6m | −10,474.3% |
| 2016 | $1.8m | — | −$24.8m | −1,376.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Xenon Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Xenon Pharmaceuticals ranks 375th of the 422 US health care companies with a page on Celsmar.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 373rd | Roivant Sciences | $8.3m | −71.6% |
| 374th | Aclaris Therapeutics | $7.8m | −58.2% |
| 375th | Xenon Pharmaceuticals | $7.5m | — |
| 376th | Ovid Therapeutics | $7.3m | 1,181.3% |
| 377th | Whitehawk Therapeutics | $7.1m | −72.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Xenon Pharmaceuticals
- How much revenue did Xenon Pharmaceuticals make in fiscal 2025?
- Xenon Pharmaceuticals reported revenue of $7.5m for fiscal 2025, compared with $0.0m in fiscal 2024.
- How much has the revenue of Xenon Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $1.8m to $7.5m: 316.0% more, an average growth of 17.2% a year.
- What was the best year for revenue at Xenon Pharmaceuticals?
- Of its last 9 fiscal years, fiscal 2020, with $32.2m.
- Where does Xenon Pharmaceuticals rank in its sector by revenue?
- It ranks 375th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Xenon Pharmaceuticals come from?
- From the annual report (Form 10-K) that Xenon Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Xenon Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2017 · 2016. More on Xenon Pharmaceuticals: the Xenon Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.